WBB Securities Reaffirms “Strong-Buy” Rating for Marker Therapeutics (NASDAQ:MRKR)

WBB Securities reissued their strong-buy rating on shares of Marker Therapeutics (NASDAQ:MRKR) in a research note published on Tuesday,Benzinga reports. WBB Securities currently has a $12.50 price objective on the stock.

Several other brokerages have also recently weighed in on MRKR. Brookline Capital Management raised Marker Therapeutics to a “strong-buy” rating in a research note on Monday, February 10th. Canaccord Genuity Group initiated coverage on shares of Marker Therapeutics in a research report on Wednesday, March 5th. They set a “buy” rating and a $8.00 target price for the company.

Marker Therapeutics Stock Performance

Shares of NASDAQ MRKR opened at $1.14 on Tuesday. The firm has a 50 day moving average price of $1.59 and a two-hundred day moving average price of $2.71. Marker Therapeutics has a 52-week low of $1.10 and a 52-week high of $5.99.

Marker Therapeutics (NASDAQ:MRKR) last posted its quarterly earnings data on Monday, March 31st. The company reported ($0.42) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.14). The company had revenue of $1.22 million during the quarter, compared to analyst estimates of $5.25 million. Marker Therapeutics had a negative net margin of 179.74% and a negative return on equity of 89.63%. On average, equities analysts forecast that Marker Therapeutics will post -0.65 earnings per share for the current year.

Institutional Trading of Marker Therapeutics

A number of institutional investors have recently bought and sold shares of MRKR. Alyeska Investment Group L.P. bought a new position in shares of Marker Therapeutics in the 4th quarter worth about $2,847,000. NEA Management Company LLC grew its stake in Marker Therapeutics by 51.7% during the fourth quarter. NEA Management Company LLC now owns 1,625,678 shares of the company’s stock worth $5,056,000 after purchasing an additional 554,250 shares during the period. Blue Owl Capital Holdings LP bought a new stake in Marker Therapeutics in the fourth quarter worth approximately $1,724,000. LPL Financial LLC acquired a new position in Marker Therapeutics in the fourth quarter valued at approximately $248,000. Finally, Northern Trust Corp boosted its holdings in shares of Marker Therapeutics by 66.9% during the 4th quarter. Northern Trust Corp now owns 54,156 shares of the company’s stock worth $168,000 after buying an additional 21,703 shares in the last quarter. Institutional investors own 22.39% of the company’s stock.

Marker Therapeutics Company Profile

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens.